http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
개별검색 DB통합검색이 안되는 DB는 DB아이콘을 클릭하여 이용하실 수 있습니다.
통계정보 및 조사
예술 / 패션
<해외전자자료 이용권한 안내>
- 이용 대상 : RISS의 모든 해외전자자료는 교수, 강사, 대학(원)생, 연구원, 대학직원에 한하여(로그인 필수) 이용 가능
- 구독대학 소속 이용자: RISS 해외전자자료 통합검색 및 등록된 대학IP 대역 내에서 24시간 무료 이용
- 미구독대학 소속 이용자: RISS 해외전자자료 통합검색을 통한 오후 4시~익일 오전 9시 무료 이용
※ 단, EBSCO ASC/BSC(오후 5시~익일 오전 9시 무료 이용)
'스콜라' 이용 시 소속기관이 구독 중이 아닌 경우, 오후 4시부터 익일 오전 7시까지 원문보기가 가능합니다.
Hollow type suppositories inserted polyvinyl alcohol (PVA) hydrogel capsule containing propranolol. HCl (PPH) were prepared using different bases, polyethylene glycol (PEG), Witepsol H-15(WH-15) and Witepsol W-35 (WW-35) to improve the controlled release of PPH. The release of PPH from the hollow type suppository inserted PVA hydrogel capsule was retarded than that from PEG, WH-15, or WW-35 hollow type suppositories in rat rectal cavity. When the suppositories were administered to rats, the controlled release of PPH was proved by the plasma concentration-time profiles of PPH. No significant difference (p<0.05) among the three different hollw type suppositories was observed in terms of AUC and MRT of PPH. WH-15 hollow type suppository inserted 12% of PVA hydrogel capsule caused irritation to rat rectal mucosa. However, the WH-15 hollow type suppository inserted PVA hydrogel capsule caused no severe irritation on rectal mucosa. The application of the hollow type suppositories using PVA in sustained rectal delivery of drugs might be feasible.
배경 : 장바이러스(enterovirus)는 무균수막염, 호흡기질환, 피부병변, 심근염, 뇌염 등의 다양한 증상을 유발할 수 있다. 감염의진단은 항체검사와 숙주세포를 이용한 배양법 및 중합효소연쇄반응에 의존해 왔으나 낮은 민감도가 문제가 되어 왔다. 이러한 단점을 보완하기 위해 저자들은 실시간-중합효소연쇄반응의 장점을이용한 장바이러스 검출법의 유용성을 평가하였다.방법 : 무균수막염이 의심되어 뇌척수액 검체를 채취한 50명을대상으로 세 종류의 각기 다른 표적을 대상으로 시행한 역전사중합효소연쇄반응과 실시간-이중-역전사중합효소연쇄반응을 시행하였다. 이 중 4명의 환자에 대해 바이러스 배양검사를 시행하였다.결과 : 세 종류의 각기 다른 표적을 대상으로 시행한 중합효소연쇄반응의 결과 각 26.0%, 40.0%, 46.0%의 장바이러스 검출률을 보였으며 바이러스 배양법의 양성률은 6.8%였다. 실시간-중합효소연쇄반응의 장바이러스 검출률은 86.0%였다.
송윤경,진선경,한의식,안미령,정주연,이이다,조일영,김동섭,지은희,박효영,오정미,신원,이선희,김인규,Song,,Yun-Kyoung,Jin,,Sun-Kyung,Han,,Eui-Sik,Ahn,,Mee-Ryung,Jung,,Ju-Yeon,Lee,,Rhee-Da,Cho,,Il-Yong,Kim,,Dong-Sub,Ji,,Eun-Hee,Park,,Hyo-Young,Oh, 대한약학회 2011 약학회지 Vol.55 No.4
'스콜라' 이용 시 소속기관이 구독 중이 아닌 경우, 오후 4시부터 익일 오전 7시까지 원문보기가 가능합니다.
Gastritis is the most common disease among Korean. The demand for the development of gastritis drugs has been increasing. Currently, however, there is no guideline available for the clinical evaluation of gastritis drugs worldwide. As a consequence, domestic and international pharmaceutical companies make errors in the drug development processes, and it becomes difficult for them to establish the scientific validity and objectivity of newly developed drugs. The objective of this study was to develop the Guideline for Clinical Trials Evaluation of Gastritis which can be used in improving the quality and consistency of clinical trials. First, we collected and reviewed the clinical trials on gastritis drugs that were available from Japan Pharmaceuticals and Medical Devices Agency and Korea Food and Drug Administration (KFDA), and investigated the recent research trends on clinical trials of gastritis drugs. Reviewers from KFDA and National Institute of Food and Drug Safety Evaluation and scientific experts from the pharmaceutical industries developed the guidelines through regularly scheduled meetings. Opinions and consultation from academic fields and industry experts were also obtained. This project will provide the clinical trial practitioners, investigator and reviewers the scientific and rational guidelines for performance and evaluation of clinical trials for gastritis drugs. Furthermore, we hope this guideline contributes to establishing the national competitiveness, improving the quality of clinical trial, and encouraging researches on drug development for gastritis.
We all human beings, should be reached the terminal of life in the world. There is the only difference between that comes suddenly or slowly. Persons who should be come the terminal stage suddenly due to disease, especially, malignancy, are Hospice patients. Hospice work is the work of all of us because anyone, anywhere, whenever can be suffered in terminal stage. The characters of Hospice-care are total care of wholistic human beings, comprehensive total assessment of the life and the team work composed of diverse team-members, for example, doctors, nurses, social workers, physical therapists, psychologists, ministers & volunteers. The care manager of the total care(the coordinator of Hospice care), should be worked systemically and, rationally. The comprehensive assessment concept should be entered to the infra-consultant of terminal care-program. The care manager should be have the ability of comprehensive assessment for terminal patients. It will also help standardization of Hospice, and application of medical insurance and social security.
This study has been conducted to investigate the amount of residual sulfur dioxide for herbal medicines of 30 species which are purchased in 13 different regions (Bonghwa, Busan, Chunju, Jecheun, Kwangju, Keumsan, Seoul, Taeku, Cheungdu, Xian, Beijing, Tokyo and Osaka). The sulfur dioxide residues were determined in the collected 386 samples by the modified Monier-Williams method. The residues of sulfur dioxide in 386 samples ranged from ND (under detection limit) to 2808 ppm. The sulfur dioxide in Cassiae Semon, Cinnamomi Romulus, Cervi Cornu, Hoelen, Crataegi Fructus, Artemisiae Argyi Herba, Scolopendrae Corpus, Schizandrae Fructus and Cyperi Rhizoma were detected under the detection limit regardless of the collected regions. The sulfur dioxide residues in herbal medicines collected in domestic regions were relatively lower than those in foreign regions. There are no standards for sulfur dioxide residual limits of herbal medicines in Korea. This results will provide the scientific basis for the standardization of sulfur dioxide residues in Korea Pharmacopoeia.
Glucuronidation by the uridine diphosphateglucuronosy- ltransferase 1A enzymes (UGT1As) is a major pathway for elimination of particular drugs and endogenous substances, such as bilirubin. We examined the relation of eight single nucleotide polymorphisms (SNPs) and haplotypes of the UGT1A gene with their clinical factors. For association analysis, we genotyped the variants by direct sequencing analysis and polymerase chain reaction (PCR) in 218 healthy Koreans. The frequency of UGT1A1 polymorphisms, -3279T>G, -3156G>A, -53 (TA)6>7, 211G>A, and 686C> A, was 0.26, 0.12, 0.08, 0.15, and 0.01, respectively. The frequency of -118 (T)9>10 of UGT1A9 was 0.62, which was significantly higher than that in Caucasians (0.39). Neither the -2152C>T nor the -275T>A polymorphism was observed in Koreans or other Asians in comparison with Caucasians. The -3156G>A and -53 (TA)6>7 polymorphisms of UGT1A were significantly associated with platelet count and total bilirubin level (p=0.01, p=0.01, respectively). Additionally, total bilirubin level was positively correlated with occurrence of the UGT1A9-118 (T)9>10 rare variant. Common haplotypes encompassing six UGT1A polymorphisms were significantly associated with total bilirubin level (p=0.01). Taken together, we suggest that determination of the UGT1A1 and UGT1A9 genotypes is clinically useful for predicting the efficacy and serious toxicities of particular drugs requiring glucuronidation.